Emerald Mutual Fund Advisers Trust Sells 154,973 Shares of Collegium Pharmaceutical, Inc. $COLL

Emerald Mutual Fund Advisers Trust decreased its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 28.1% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 395,661 shares of the specialty pharmaceutical company’s stock after selling 154,973 shares during the period. Emerald Mutual Fund Advisers Trust’s holdings in Collegium Pharmaceutical were worth $13,844,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in COLL. Eastern Bank increased its stake in Collegium Pharmaceutical by 487.5% in the 3rd quarter. Eastern Bank now owns 54,843 shares of the specialty pharmaceutical company’s stock worth $1,919,000 after acquiring an additional 45,508 shares during the last quarter. SG Americas Securities LLC grew its holdings in shares of Collegium Pharmaceutical by 215.6% during the third quarter. SG Americas Securities LLC now owns 28,978 shares of the specialty pharmaceutical company’s stock worth $1,014,000 after purchasing an additional 19,796 shares in the last quarter. KLP Kapitalforvaltning AS increased its position in shares of Collegium Pharmaceutical by 7.7% in the third quarter. KLP Kapitalforvaltning AS now owns 21,100 shares of the specialty pharmaceutical company’s stock worth $738,000 after purchasing an additional 1,500 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in Collegium Pharmaceutical by 90.5% in the third quarter. Assenagon Asset Management S.A. now owns 195,589 shares of the specialty pharmaceutical company’s stock valued at $6,844,000 after purchasing an additional 92,898 shares in the last quarter. Finally, Texas Permanent School Fund Corp lifted its position in Collegium Pharmaceutical by 8.0% during the second quarter. Texas Permanent School Fund Corp now owns 99,208 shares of the specialty pharmaceutical company’s stock valued at $2,934,000 after purchasing an additional 7,378 shares during the last quarter.

Insiders Place Their Bets

In other Collegium Pharmaceutical news, EVP Scott Dreyer sold 17,600 shares of the business’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $48.17, for a total value of $847,792.00. Following the completion of the sale, the executive vice president owned 103,613 shares in the company, valued at approximately $4,991,038.21. The trade was a 14.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Rita J. Balice-Gordon sold 3,650 shares of the stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $47.03, for a total value of $171,659.50. Following the sale, the director directly owned 52,629 shares of the company’s stock, valued at approximately $2,475,141.87. This trade represents a 6.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 51,250 shares of company stock valued at $2,235,352 in the last ninety days. Company insiders own 2.51% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Wall Street Zen raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Barclays reduced their target price on Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating on the stock in a research note on Friday, January 9th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Collegium Pharmaceutical in a research note on Monday, December 29th. Zacks Research cut Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Finally, Needham & Company LLC raised their price objective on Collegium Pharmaceutical from $48.00 to $56.00 and gave the company a “buy” rating in a report on Thursday, January 8th. Five investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Collegium Pharmaceutical presently has a consensus rating of “Moderate Buy” and a consensus price target of $52.80.

Collegium Pharmaceutical Stock Performance

NASDAQ COLL opened at $47.10 on Friday. The company has a 50-day simple moving average of $47.21 and a two-hundred day simple moving average of $39.53. Collegium Pharmaceutical, Inc. has a 12-month low of $23.23 and a 12-month high of $50.79. The firm has a market cap of $1.49 billion, a price-to-earnings ratio of 29.25 and a beta of 0.60. The company has a quick ratio of 1.27, a current ratio of 1.36 and a debt-to-equity ratio of 2.71.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Thursday, November 6th. The specialty pharmaceutical company reported $2.25 earnings per share for the quarter, beating analysts’ consensus estimates of $1.89 by $0.36. The company had revenue of $209.36 million during the quarter, compared to analyst estimates of $191.25 million. Collegium Pharmaceutical had a return on equity of 102.03% and a net margin of 7.72%.Collegium Pharmaceutical’s revenue for the quarter was down 18.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.61 EPS. On average, equities analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.